<DOC>
	<DOCNO>NCT00405119</DOCNO>
	<brief_summary>Current treatment gastroesophageal reflux disease ( GERD ) confirm unmet need patient , base slow onset action inability provide 24-hour gastric-acid suppression . Clinical data AH234844 demonstrate rapid onset action , high potency , prolonged duration effect . The present study endeavor , part , compare lavoltidine two GERD drug , NEXIUM ranitidine .</brief_summary>
	<brief_title>A Study To Investigate The Effectiveness Of AH234844 ( Lavoltidine ) Compared With NEXIUM And Ranitidine .</brief_title>
	<detailed_description>A three-part study healthy male volunteer determine effective four different lavoltidine dos gastric pH compare effective dose NEXIUM ( esomeprazole ) 40mg inhibition gastric-acid secretion ranitidine ( 300mg/day ) amount pharmacodynamic tolerance</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Loxtidine</mesh_term>
	<criteria>Inclusion criterion : Subject must Body Mass Index ( BMI ) 1930 kg/m2 Subject present abnormal clinical lab finding Subject able tolerate nasogastric pH electrode . Exclusion criterion : Subject Helicobacterpositive C13 urea breath test Subject baseline median 24hour gastric pH &gt; 3 For Part B study , subject CYP 2C19 poor metabolizers .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>tolerance</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>ranitidine</keyword>
	<keyword>esomeprazole</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>gastroesophageal reflux disease ( GERD )</keyword>
	<keyword>AH23844</keyword>
</DOC>